慢性乙型肝炎患者血清可溶性E-钙黏蛋白表达与氧化应激的相关性分析

肝脏 ›› 2021, Vol. 26 ›› Issue (1): 19-21.

慢性乙型肝炎患者血清可溶性E-钙黏蛋白表达与氧化应激的相关性分析

许俊, 谢国艳, 黄敏

202150 上海交通大学医学院附属新华医院崇明分院消化内科(许俊,黄敏);上海中医药大学附属市中医医院检验科(谢国艳)

收稿日期:2020-06-18 出版日期:2021-01-31 发布日期:2021-02-26
通讯作者: 谢国艳,Email:zhjjxj@163.com
基金资助:
上海市卫生和计划生育委员会基金项目(ZY-FWTX-6031)

The correlation between serum soluble E-cadherin expression and oxidative stress in patients with chronic hepatitis B

XU Jun¹, XIE Guo-yan², HUANG Min¹

Department of Gastroenterology, Chongming Branch, Xinhua Hospital affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 202150, China

Received:2020-06-18 Online:2021-01-31 Published:2021-02-26
Contact: XIE Guo-yan,Email:zhjjxj@163.com

摘要/Abstract

摘要： 目的探讨慢性乙型肝炎(Chronic hepatitis B,CHB)患者血清可溶性E-钙黏蛋白(soluble E-cadherin,sE-cadherin)表达与氧化应激的相关性。方法选择2018年1月至2019年12月在上海新华医院崇明分院门诊和住院治疗的54例CHB患者,根据CHB的严重程度分为轻度16例,中度20例和重度18例,选择同期健康体检者20名作为对照组。检测血清中AST、ALT、sE-cadherin、GSH、MDA、NOX2、SOD和HBV DNA水平,进行Pearson相关分析;采用二分类logistic回归分析CHB严重程度的影响因素。结果与对照组比较,各CHB组患者血清中AST、ALT、sE-cadherin、MDA、NOX2和HBV DNA浓度增加[AST:(72.59±10.42)、(107.59±8.24)、(160.13±24.84)比(28.51±4.67)U/L,ALT:(64.27±8.91)、(118.43±15.37)、(194.30±12.61)比(24.18±5.64)U/L,sE-cadherin:(566.27±73.16)、(671.51±80.43)、(735.65±43.29)比(309.51±43.28)pg/mL,MDA:(12.58±2.37)、(17.35±3.51)、(24.35±4.18)比(7.59±0.83)nmol/mL,NOX2:(1837.25±106.25)、(2766.52±428.14)、(2766.52±428.14)比(972.58±34.82)pg/mL,HBV DNA:(42.27±8.37)、(76.26±15.52)、(101.64±8.94)lg拷贝/mL],GSH和SOD浓度降低[GSH:(9.92±1.58)、(5.23±0.94)、(3.77±0.51)比(15.16±2.26)ng/mL,SOD:(140.75±15.26)、(127.31±10.58)、(97.35±10.94)比(168.29±24.62)U/mL],且随着病情的加重呈相应的变化(P<0.05);血清中sE-cadherin与AST、ALT、HBV DNA、MDA和NOX2呈正相关(r=0.591、0.538、0.675、0.527、458,P<0.05);血清中sE-cadherin与GSH和SOD 呈负相关(r=-0.499、-0.492,P<0.05);将是否为重度CHB作为因变量进行多因素分析,结果sE-cadherin、HBV DNA和NOX2是重度CHB的影响因素(P<0.05)。结论 CHB患者血清中sE-cadherin浓度随疾病程度加重而增加,其与患者机体氧化应激呈正相关。

关键词: 慢性乙型肝炎, 可溶性E-钙黏蛋白, 氧化应激

Abstract: Objective To investigate the correlation between serum soluble E-cadherin expression and oxidative stress in patients with chronic hepatitis B.Methods Fifty-four HBsAg-positive patients that were diagnosed as HBV infection were selected in this study. They were divided into mild (16 cases), moderate (20 cases) and severe (18 cases) subgroups according to the severity of CHB. Twenty healthy subjects were also enrolled as the control group. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), sE-cadherin, glutathione (GSH), Malondialdehyde (MDA), NADPH oxidase 2 (NOX2), superoxide dismutase (SOD) and HBV DNA load were detected. The data were applied to Pearson correlation analysis. The influencing factors for the severity of CHB were analyzed by multivariate binary logistic regression.Results Compared with the control group, the serum levels of AST, ALT, sE-cadherin, MDA, NOX2 and HBV DNA were significantly increased [AST: (72.59±10.42), (107.59±8.24), (160.13±24.84) vs (28.51±4.67) U/L, ALT: (64.27±8.91), (118.43±15.37), (194.30±12.61) vs (24.18±5.64) U/L, sE-cadherin: (566.27±73.16), (671.51±80.43), (735.65±43.29) vs (309.51±43.28) pg/mL, MDA: (12.58±2.37), (17.35 ±3.51), (24.35±4.18) vs (7.59±0.83) nmol/mL, NOX2: (1837.25±106.25), (2766.52±428.14), (2766.52±428.14) vs (972.58±34.82) pg/mL, and HBV DNA: (42.27±8.37), (76.26±15.52), (101.64±8.94)log₁₀ copies/mL, On the contrary, the levels of GSH and SOD significantly decreased [GSH: (9.92±1.58), (5.23±0.94), (3.77±0.51) vs (15.16±2.26) ng/mL, SOD: (140.75±15.26), (127.31±10.58), (97.35±10.94) vs (168.29±24.62) U/mL] in each CHB group, and changed accordingly with the aggravation of the disease (P<0.05). The serum levels of sE-cadherin were positively correlated with AST, ALT, HBV DNA, MDA and NOX2 (r=0.591, 0.538, 0.675, 0.527, 458, respectively, P<0.05), whereas negatively correlated with GSH and SOD (r=-0.499, -0.492, P<0.05). The result of multivariate analysis showed that sE-cadherin, HBV DNA and NOX2 were the influencing factors for severe CHB (P<0.05).Conclusion Serum sE-cadherin in patients with chronic hepatitis B viral infection increased with the severity of the disease, which was positively associated with the oxidative stress in the patients.

Key words: Chronic hepatitis B, Disease severity, Soluble E-cadherin, Oxidative stress

许俊, 谢国艳, 黄敏. 慢性乙型肝炎患者血清可溶性E-钙黏蛋白表达与氧化应激的相关性分析[J]. 肝脏, 2021, 26(1): 19-21.

XU Jun, XIE Guo-yan, HUANG Min. The correlation between serum soluble E-cadherin expression and oxidative stress in patients with chronic hepatitis B[J]. Chinese Hepatolgy, 2021, 26(1): 19-21.

参考文献

[1] Cai J, Han T, Nie C, et al. Biomarkers of oxidation stress, inflammation, necrosis and apoptosis are associated with hepatitis B-related acute-on-chronic liver failure. Clin Res Hepatol Gastroenterol, 2016, 40:41-50.
[2] Silva RDS, lombardi APG, Deborah Simão de Souza, et al. Activation of estrogen receptor beta (ERβ) regulates the expression of N-cadherin, E-cadherin and β-catenin in androgen-independent prostate cancer cells. Int J Biochem Cell Biol, 2018, 96:40-50.
[3] Wang S, Yan Y, Cheng Z, et al. Sotetsuflavone suppresses invasion and metastasis in non-small-cell lung cancer A549 cells by reversing EMT via the TNF-α/NF-κB and PI3K/AKT signaling pathway. Cell Death Discov, 2018, 4:26-41.
[4] Rosner M, Hengstschläger M. letter to the editor: human pluripotent stem cells release oncogenic soluble E-cadherin. Stem Cells, 2016, 34:2443-2446.
[5] Giovannini C, Minguzzi M, Genovese F, et al. Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. Oncotarget, 2016, 7:39609-39626.
[6] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015 年更新版).临床肝胆病杂志,2015,31:1941-1960.
[7] Cheng SF, Jiang YH, Kuo HC. Urothelial dysfunction and chronic inflammation are associated with increased bladder sensation in patients with chronic renal insufficiency. Int Neurourol J, 2018, 22:46-54.
[8] 黄坚, 沈佳庆, 汤海波, 等. sE-Cadherin早期评价急性胰腺炎严重程度的临床价值. 中国医科大学学报, 2014, 43:870-873.
[9] Qiao J, Qi K, Chu P, et al. Infusion of endothelial progenitor cells ameliorates liver injury in mice after haematopoietic stem cell transplantation. Liver Int, 2015, 35:2611-2620.
[10] 黄丹, 王彦, 张福杰. 北京地区HIV/HBV合并感染者与HBV单独感染者中HBV基因型分布. 中国艾滋病性病, 2019,25:227-230.
[11] Huang H, Wang J, Li W, et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals. J Clin Virol, 2018,18: 99-100.
[12] Zhong L , Shu W , Dai W , et al. Reactive oxygen species-mediated c-Jun NH2-terminal kinase activation contributes to hepatitis B virus X protein-induced autophagy via regulation of the Beclin-1/Bcl-2 interaction. J Virol, 2017, 91:1-17.
[13] Ruban VV, Archana PT , Sundararajan M , et al. Inflammation and oxidative stress in corneal tissue in experimental keratitis due to fusarium solani: amelioration following topical therapy with voriconazole and epigallocatechin gallate. Mycoses, 2018, 61:159-171.
[14] Emmerson A, Trevelin SC, Mongue-Din H, et al. Nox2 in regulatory T cells promotes angiotensin II-induced cardiovascular remodeling. J Clin Invest, 2018, 128:3088-3101.

[1]	林彬彬, 肖志鸿, 王菲, 阮清发, 汤钰菁, 欧阳丽娟. 慢性乙型肝炎恩替卡韦经治后联合长效干扰素的疗效预测分析[J]. 肝脏, 2021, 26(1): 27-32.
[2]	冯少阳, 李广明, 苏航. 瞬时弹性成像对慢性乙型肝炎合并非酒精性脂肪性肝病患者肝纤维化的评估价值[J]. 肝脏, 2021, 26(1): 44-46.
[3]	赵海东, 陈灵峰, 林巧欣, 李艺芳. 聚乙二醇干扰素α短期治疗HBsAg水平极低的非活动性HBsAg携带者的疗效观察[J]. 肝脏, 2020, 25(9): 937-939.
[4]	高文, 杨雪, 窦爱华, 惠威, 刘梅, 徐斌, 段钟平. 维生素D缺乏对乙型肝炎患者的影响[J]. 肝脏, 2020, 25(9): 940-942.
[5]	陈拉斯, 王婷婷, 王善志. 连续性血液净化对脓毒血症患者肝损伤的保护作用[J]. 肝脏, 2020, 25(9): 1003-1004.
[6]	周莹, 杨俊梅, 张桂珍, 甄明慧. 学龄前HBeAg阴性慢性乙型肝炎患儿临床特点分析[J]. 肝脏, 2020, 25(6): 605-606.
[7]	吴智慧, 丁媛. 慢性乙型肝炎肝硬化患者恩替卡韦抗病毒干预后肝脏弹性成像定量变化观察[J]. 肝脏, 2020, 25(6): 630-632.
[8]	贺尼娅, 王琳. 慢性乙型肝炎患者血清胆固醇与肝纤维化的相关性研究[J]. 肝脏, 2020, 25(6): 645-647.
[9]	钟大明, 蓝柏钊, 欧超兰, 陈开革, 温静, 李嘉丽, 周甦, 莫穆隆, 梁柱石. HBsAg不同载量的HBeAg阳性慢性乙型肝炎对恩替卡韦治疗应答比较[J]. 肝脏, 2020, 25(5): 505-507.
[10]	孙蔚, 杨星. 瞬时弹性成像和声脉冲辐射力成像技术诊断慢性乙型肝炎肝纤维化的价值[J]. 肝脏, 2020, 25(5): 534-535.
[11]	卢君瑶, 王登宇, 尹东林, 白玉盘, 许洁. HBV相关肝细胞癌的临床特征及危险因素分析[J]. 肝脏, 2020, 25(3): 285-287.
[12]	沈张平, 王钦君, 季沈杰. 血清miR127-3P与原发性肝癌的相关性研究[J]. 肝脏, 2020, 25(3): 302-305.
[13]	薛宏丽. HBsAg定量在慢性乙型肝炎治疗中的意义[J]. 肝脏, 2020, 25(3): 308-310.
[14]	梅栖榕, 杨丽, 沈毅. 慢性乙型肝炎患者长期服用阿德福韦酯与肾性低磷血症的相关性[J]. 肝脏, 2020, 25(3): 311-313.
[15]	孔媛媛, 魏巍, 单姗, 马红, 欧晓娟, 徐小元, 段钟平, 侯金林, 魏来, 尤红, 贾继东, 中国消除乙肝临床科研平台(CR-HepB)研究组. 乙型肝炎肝硬化患者的临床特征与抗病毒治疗模式变化[J]. 肝脏, 2020, 25(2): 123-127.